ESMO 2022 | SURPASS: Mechanism of action of ADP-A2M4CD8

David Hong, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains the mechanism of action of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, which is currently being trialled in the Phase I SURPASS trial (NCT04044859) in previously treated patients with unresectable or metastatic tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.